1. FDA OKs an eighth use for JNJ’s Xarelto — Roche’s Rituxan shows superiority in autoimmune skin condition — Sun Pharma launches dry eye disease treatment in US — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

HARMONY

Discussion in 'Biotech Startups' started by anonymous, Apr 27, 2018 at 9:30 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Wow, this will be tough,
    -No cataplexy, not even in the clinical data section (this is really bad)
    -No data on maintenance of wakefulness
    -Decent data on ESS, but not as good as Sunosi

    On the positive, it's not scheduled but I am not sure that is going to mean much

    I mean this sincerely, I wish the Harmony team good luck.
     
  2. anonymous

    anonymous Guest

    WTH? Are main tag line is ‘non scheduled narcolepsy drug’

    Who fucked up the cataplexy indication???

    Fuck
     
  3. anonymous

    anonymous Guest

    Calm down. Cataplexy is not important.
     
  4. anonymous

    anonymous Guest

    Seriously? Our daytime sleepiness data is worse than providgil. I feel like I’ve been completely mislead. And management is too quiet.
     
  5. anonymous

    anonymous Guest

    All are jealous and should be
     
  6. anonymous

    anonymous Guest

    Should we be worried?
    I left a good company to come here and like what I have seen but this isn’t the indication I thought we would get. My old company has already asked me back once?
     
  7. anonymous

    anonymous Guest

    It’s “provigil”... and I think it was inferior to provigil
     
  8. anonymous

    anonymous Guest

    We’re $ucked
     
  9. anonymous

    anonymous Guest

    You might be correct.

    Wakix inferior efficacy compared to other EDS drugs, $50,000 - $100,000?, no cataplexy indication, not scheduled but label has drug interactions, QT interval prolongation, hepatic issues, reduction contraception efficacy, specialty pharmacy paperwork. Wakix on life support.
     
  10. anonymous

    anonymous Guest

     
  11. anonymous

    anonymous Guest


    You Are Toast !!!!
     
  12. anonymous

    anonymous Guest

    All the jealous people just wait till we launch
     
  13. anonymous

    anonymous Guest

    All you whiners don’t deserve to be apart of this company if you can’t sell this drug then your not qualified. We hired the best of the best so some of you obviously lied during the interview. No one said pitolisant would be an easy sell which is why we only have the best. I left my comfortable cushy company for a real challenge and all of you need to man up grow a pair. When we launch you swill see how our drug is more favorable because it’s lack of scheduling. That’s all it takes to be one step ahead. It’s up to you to seal the deal. Our data is good don’t compare to other meds otherwise you’ll be distracted. Focus on our moa and the fact we are not scheduled like the other drug that doctors worry about abuse liability. The poster before me is right. All the jealous people are just talking crap.
     
  14. anonymous

    anonymous Guest

    Spellcheck your claim and I might have more respect for you as my competitor
     
  15. anonymous

    anonymous Guest

    Wakix interacts with the CYP3A4 and CPY2D6

    Wakix makes birth control ineffective

    Risk with Hepatic and Renal

    And Harmony is not know by the sleep specialists like JAZZ

    Lock the door and turn out the lights

    You’re Toast !!!!
     
  16. anonymous

    anonymous Guest

    Add to the List

    Interacts with the CYP450 3A4. And the CYP450 2D6

    Makes Birth Control ineffective

    Hepatic and Renal Risk Precautions

    Please turn off the lights and shut the door

    You’re Toast !!!!!
     
  17. anonymous

    anonymous Guest

    This is quite funny. Whether you work for the company or will compete against it, the drug interaction profile is minimal. All drugs for narcolepsy carry a similar warning around either birth control or teratogenicity.

    QT prolongation is minimal. Nothing compared to drugs such as antipsychotics (barely moves the needle at maximum recommended dose).

    Can’t give to patients with severe hepatic or patients with End Stage Renal Disease. Ok

    Sucks it doesn’t have cataplexy indication at the moment. Slows the uptake but still will have a role.
     
  18. anonymous

    anonymous Guest

    Another jealous person and you should be, we’re the highest paid reps in the industry and just wait till we launch
     
  19. anonymous

    anonymous Guest

    Hate to break it to you moron, but you aren’t even in the Top 50% for compensation versus Biologics, Rare Disease, or Niche Specialty Companies

    BTW - Your “stock” is also worthless because Paragon controls the rights to a move and with their current structure and losses across the board, they will not divest Harmony regardless of success or failure

    You aren’t smart, you most likely weren’t in the Top 5 choices for the job you now reside in, and your ignorance couldn’t be more hysterical which is why you are in that job...until you launch and get blasted, then you will have triumphed over your ignorance with your failure
     
  20. anonymous

    anonymous Guest

    only a jealous and upset job seeker would spend so much time on here complaining about Harmony.